Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy. (7th February 2014)
- Record Type:
- Journal Article
- Title:
- Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy. (7th February 2014)
- Main Title:
- Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy
- Authors:
- Shankar, Ananth
Hayward, Janis
Kirkwood, Amy
McCarthy, Keith
Hewitt, Martin
Morland, Bruce
Daw, Stephen - Abstract:
- <abstract abstract-type="main" id="bjh12768-abs-0001"> <title>Summary</title> <p>The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone treatment strategy. Between 2000 and 2005<bold>, </bold> 80 children with relapsed [<italic>n</italic> = 69] or primary refractory [<italic>n</italic> = 11] HL were treated on a standardized treatment protocol of 4–6 cycles of EPIC [etoposide, prednisolone, ifosfa3mide and cisplatin] chemotherapy. Radiotherapy was recommended to all relapsed sites. High dose therapy with stem cell rescue [SCT] was recommended for patients with poor response. The 5‐year overall survival [OS] and progression‐free survival from relapse was 75·8% [64·8–83·9] and 59·9% [48·3–69·7] respectively. Duration of first remission was strongly associated with OS; risk of death was decreased by 53% [Hazard ratio (HR): 0·47, 95% confidence interval (CI): 0·19–1·18] for those with a time from end of treatment to relapse of 3–12 months (compared to <3 months) and reduced by 80% (HR 0·20, 95% CI: 0·04–0·90) for those >12 months after end of treatment. Other poor prognostic factors included advanced stage disease at relapse and B symptoms at first diagnosis. The most important factor associated with salvage failure was time to relapse<bold>.</bold> Survival outcome in children with primary refractory HL is poor.</p> </abstract>
- Is Part Of:
- British journal of haematology. Volume 165:Number 4(2014:May)
- Journal:
- British journal of haematology
- Issue:
- Volume 165:Number 4(2014:May)
- Issue Display:
- Volume 165, Issue 4 (2014)
- Year:
- 2014
- Volume:
- 165
- Issue:
- 4
- Issue Sort Value:
- 2014-0165-0004-0000
- Page Start:
- 534
- Page End:
- 544
- Publication Date:
- 2014-02-07
- Subjects:
- Hematology -- Periodicals
Blood -- Diseases -- Periodicals
616.15 - Journal URLs:
- http://www.blacksci.co.uk/%7Ecgilib/jnlpage.bin?Journal=bjh&File=bjh&Page=aims ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2141 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bjh.12768 ↗
- Languages:
- English
- ISSNs:
- 0007-1048
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2309.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4035.xml